E
Equillium Inc (EQ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$1.15
-0.14 (-10.85%)
Market Cap: $106.20M
Last updated: Nov 17, 2026 at 11:05 AM ET
Equillium Inc (EQ) Valuation Multiples
Equillium (EQ) trades at 29.3x sales and 2.4x book value. Its P/B of 2.4x is above its 5-year median of 1.7x. Its forward P/E is 1.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 1.5x |
| Price to sales | 29.3x |
| Price to book | 2.4x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 2.4x | 1.7x | N/A |
Valuation History
Over the 3 of the 8 year ends shown that have a P/S, its P/S ranged from 0.7x in 2024 to 2.3x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.55 | N/A | 5.0x |
| 2024 | $0.75 | 0.7x | 1.4x |
| 2023 | $0.72 | 0.7x | 1.1x |
| 2022 | $1.06 | 2.3x | 1.1x |
| 2021 | $3.77 | N/A | 1.7x |
| 2020 | $5.35 | N/A | 1.9x |
| 2019 | $3.38 | N/A | 1.4x |
| 2018 | $8.16 | N/A | 2.0x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EQ
What is EQ's forward P/E ratio?
Equillium has a forward P/E ratio of 1.5x.
Is EQ stock overvalued?
GNG's valuation label for EQ is Overvalued.
What is EQ's price to sales ratio?
Equillium has a price to sales ratio of 29.3x.
EQ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors